Compare GSK plc (GSK) vs Lufax Holding Ltd (LU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Lufax Holding Ltd — how do they compare? GSK plc trades at $52.44 (market cap $101.34B), while Lufax Holding Ltd trades at $1.33 (market cap $2.41B). The key difference: GSK plc is far larger — about 42× Lufax Holding Ltd's market cap, and GSK plc pays a 3.49% dividend while Lufax Holding Ltd pays none. Which is the better fit depends on your goals.
| GSK | LU | |
|---|---|---|
Market Cap | $101.34B | $2.41B |
Sector | Health | Technology |
52-Week High | $61.18 | $4.40 |
52-Week Low | $36.20 | $1.23 |
Enterprise Value | $121.95B | — |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
LU trades at $1.33, up 3.1% today, but technical indicators are bearish with moving averages signaling a downtrend. The company reported a net loss of $2.1 billion in 2025, with negative profit margins and returns. Multiple class-action lawsuits filed in May 2026 allege securities fraud, creating significant legal overhangs.
The outlook is challenged by persistent losses and legal risks, though low valuation ratios like P/S of 0.34 and P/B of 0.1 may attract value investors. Analyst consensus is moderately positive with 62% buy ratings, but investors face substantial downside risk from ongoing litigation and profitability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Lufax Holding Ltd
Lufax Holding Ltd is a leading financial technology (fintech) platform in China. The company operates a technology-driven personal financial services platform that offers a wide range of loans and wealth management products to its users. Lufax primarily serves the rapidly growing wealth and consumption needs of China’s mass affluent and affluent populations through a combination of its digital platform and an extensive offline network.
Read more on LU →
